 | Related Articles |
Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism.
JAMA. 2015 Jul 7;314(1):72-3
Authors: Middeldorp S, Hutten BA
Abstract
CLINICAL QUESTION: Is long-term (≥3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE?
BOTTOM LINE: Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality.
PMID: 26151268 [PubMed - indexed for MEDLINE]